This was the stock's second consecutive day of losses.
The stock's fall snapped a four-day winning streak.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
It prevents pain signals from reaching the brain. Vertex Pharmaceuticals Inc. dominated the market today, gaining €24.45 (5.800%). With 61 Buy predictions and not a single Sell prediction Vertex ...
Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vertex Inc. (NASDAQ:VERX ... Not to be confused with Vertex Pharmaceuticals, Vertex is a company specializing in consulting services and tax preparation ...
This is the online version of STAT’s email newsletter Health Care Inc, delivered to your ... UnitedHealthcare likely to cover Vertex’s pain drug Vertex Pharmaceuticals received FDA approval ...
In a report released yesterday, Jessica Fye from J.P. Morgan maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...
Vertex Pharmaceuticals (VRTX) ended the recent trading session at $470.37, demonstrating a +1.88% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback